Internal Medicine, Endocrinology, Diabetes, & Metabolism · Metairie, LA
NPI
1750369161
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
3901 Houma Blvd, Suite 103
Metairie, LA, 70006
Phone (504) 455-1300
Groups this clinician bills Medicare through
Medicare paid, 2024
$81K
980 services
Medicare patients, 2024
426
Average age 73
Drug cost, 2024
$4.2M
10,262 prescriptions
Company payments, 2025
$3,122
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Tuan-Huy V Tran was code 99214 (office e&m - established), 657 times for 382 patients. In total Tuan-Huy V Tran billed 980 services in 14 codes, and Medicare paid $81K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-07-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 657 | 382 | $95.02 | $62K |
| 95251 Test - Miscellaneous | Office | 125 | 63 | $26.12 | $3,266 |
| 76536 Ultrasound - Nonspecific | Office | 104 | 102 | $81.10 | $8,434 |
| 99233 Hospital E&M - Subsequent | Facility | 16 | 11 | $88.86 | $1,422 |
| 10005 Other Organ Systems | Office | 15 | 15 | $97.80 | $1,467 |
| 99204 Office E&M - New | Office | 13 | 13 | $121.80 | $1,583 |
By year: 2022 $81K for 915 services; 2023 $77K for 876 services; 2024 $81K for 980 services.
Medicare prescription drug claims, 2024
In 2024, the drug Tuan-Huy V Tran prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,096 prescriptions and refills. In total Tuan-Huy V Tran wrote 10,262 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,096 | 3,078 | 307 | $8,720 |
| Ozempic Semaglutide | 505 | 681 | 101 | $650K |
| Glimepiride Generic | 419 | 1,217 | 128 | $4,052 |
| Mounjaro Tirzepatide | 412 | 511 | 76 | $536K |
| Metformin Hcl Generic | 399 | 1,071 | 106 | $2,357 |
| Jardiance Empagliflozin | 369 | 627 | 85 | $369K |
| Metformin Hcl Er Metformin Hcl | 349 | 889 | 97 | $3,577 |
| Synthroid Levothyroxine Sodium | 277 | 642 | 65 | $24K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 265 | 495 | 68 | $41K |
| Atorvastatin Calcium Generic | 221 | 614 | 65 | $2,405 |
| Rosuvastatin Calcium Generic | 219 | 582 | 64 | $1,912 |
| Farxiga Dapagliflozin Propanediol | 185 | 325 | 36 | $181K |
| Soliqua 100-33 Insulin Glargine/Lixisenatide | 184 | 268 | 37 | $195K |
| Novolog Flexpen Insulin Aspart | 180 | 350 | 56 | $48K |
| Methimazole Generic | 154 | 356 | 39 | $1,098 |
Brand drugs: 4,638 claims; generic drugs: 4,965 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Tuan-Huy V Tran $3,122 ($3,122 in general payments such as food, travel and fees) from 30 companies. The largest payer was Dexcom, Inc. with $441.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 19 | $441 |
| Novo Nordisk Inc NVO | 21 | $345 |
| Xeris Pharmaceuticals, Inc. | 21 | $305 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 13 | $274 |
| Beta Bionics, Inc. BBNX | 15 | $239 |
| Amgen Inc. AMGN | 13 | $233 |
| Corcept Therapeutics CORT | 11 | $226 |
| Lilly USA, LLC LLY | 10 | $175 |
| Abbott Laboratories ABT | 9 | $146 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $101 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.